423 results on '"Jiménez Yuste, Víctor"'
Search Results
2. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
3. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
4. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks
5. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
6. Inhibitors in Hemophilia B
7. Inhibitors in Hemophilia A
8. Pathophysiology of Hemophilia
9. No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
10. Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
11. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
12. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
13. Teenagers and Adolescents with Hemophilia–Need for a Specific Approach.
14. Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage
15. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of four Phase III trials
16. Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab
17. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases
18. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
19. Knee replacement surgery in a patient with acquired von Willebrand disease: a case study with recommendations for patient management
20. Cross-sectional epidemiological study to understand the approach to treatment in the routine care of patients with hemophilia B in Spain and Portugal
21. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
22. Haemophilia: Reasons for visits to the paediatric emergency department
23. Hemofilia: naturaleza de las visitas a urgencias pediátricas
24. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
25. Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
26. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
27. A post hoc comparative real‐world analysis of HEAD‐US score for joint health assessment of patients with severe haemophilia A and B in Spain.
28. Study of platelet kinetics in immune thrombocytopenia to predict splenectomy response
29. Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types
30. Haemophilia B: Where are we now and what does the future hold?
31. Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method
32. Study of platelet kinetics in immune thrombocytopenia to predict splenectomy response.
33. Association of patient, treatment and disease characteristics with patient‐reported outcomes: Results of the ECHO Registry.
34. Hematological Concepts and Hematological Perioperative Treatment
35. The Analgesic Efficacy of a COX-2 Inhibitor (Oral Celecoxib) in Adult Hemophilic Patients and Intense Joint Pain Secondary to Advanced Hemophilic Arthropathy
36. Fitusiran prophylaxis in severe haemophilia without inhibitors
37. The 2021 guidelines on the diagnosis of von Willebrand disease: A comparison with current clinical practice in Spanish centers
38. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
39. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus
40. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
41. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
42. Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia
43. Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
44. COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
45. Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery
46. Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
47. Predictive Value of Platelet Sequestration Studies in Splenectomy Response
48. Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
49. Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
50. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.